Skip to main content

Advertisement

Table 5 The association between LINE-1 methylation status and clinicopathological parameters (stage III colon cancers only)

From: Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Parameters LINE-1 methylation levels (low vs.high)
Cancer sample (n = 268) Normal LN sample (n = 268)
OR (95 % C.I.) P a OR (95 % C.I.) P a
Gender (male vs. female) 1.63 (0.971–2.747) 0.065 1.11 (0.699–1.745) 0.670
Age (≥60 years vs. <60 years) 1.23 (0.742–2.053) 0.419 0.97 (0.624–1.508) 0.893
BMI (overweight vs. normal) 1.21 (0.711–2.044) 0.487 1.56 (0.991–2.444) 0.055
Tumor location (distal vs. proximal) 0.78 (0.438–1.383) 0.393 1.14 (0.694–1.887) 0.598
Pathology
 (Mucinous vs. non-mucinous) 0.77 (0.149–4.004) 0.759 1.52 (0.361–6.387) 0.569
Differentiation
 (High grade vs. low grade) 0.58 (0.154–2.185) 0.420 0.51 (0.154–1.687) 0.270
T stage (T4 vs. T1, 2, 3) 0.99 (0.417–2.359) 0.985 0.74 (0.381–1.447) 0.382
N stage (N2 vs. N0, 1) 1.07 (0.600–1.921) 0.812 1.21 (0.720–2.039) 0.470
Microsatellite status
 (MSI-H vs. MSS + MSI-L) 0.40 (0.118–1.388) 0.150 1.02 (0.380–2.728) 0.972
Performance status (PS ≥ 1 vs. PS = 0) 1.80 (1.081–3.004) 0.024 1.20 (0.770–1.871) 0.421
  1. BMI body mass index, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, PS performance status
  2. aUnconditional logistic regression, adjusted for other selected covariates